-+ 0.00%
-+ 0.00%
-+ 0.00%

On November 20, Hanson Pharmaceuticals announced that the marketing license application for the company's innovative drug deuterosoxitinib tablets has been accepted by the State Drug Administration for adult patients with moderate to severe plaque psoriasis. This is the first domestically produced TYK2 allosteric inhibitor approved by NDA.

Zhitongcaijing·11/20/2026 11:49:14
Listen to the news
On November 20, Hanson Pharmaceuticals announced that the marketing license application for the company's innovative drug deuterosoxitinib tablets has been accepted by the State Drug Administration for adult patients with moderate to severe plaque psoriasis. This is the first domestically produced TYK2 allosteric inhibitor approved by NDA.